BiliCheck vs JM-103 in identifying neonates not at risk of hyperbilirubinemia

Costantino Romagnoli1,2*, Piero Catenazzi1, Giovanni Barone1, Lucia Giordano1, Riccardo Riccardi1, Antonio Alberto Zuppa1 and Enrico Zecca1

Abstract

Background: Transcutaneous bilirubinometry is widely used to predict hyperbilirubinemia by using several devices. The aim of this study was to compare the predictive ability of BiliCheck vs JM-103 in identifying neonates not at risk of significant hyperbilirubinemia, putting the data obtained with the two instruments on our transcutaneous bilirubin nomogram built with the BiliCheck.

Methods: Transcutaneous bilirubin (TcB) measurement was performed when jaundice appeared in newborn babies and/or just before discharge from the hospital. It was performed at the forehead with the two instruments within 5 minutes by two experienced neonatologists, each one blind to the value obtained by the other. Blood samples were drawn to obtain total serum bilirubin (TSB) levels soon after TcB measurements.

Results: A total of 627 paired-sample measurements were obtained from 298 newborn babies. Out of the total population studied, 16 newborn babies (5.4%) showed significant hyperbilirubinemia defined as TSB value >17 mg/dL, or as need for phototherapy treatment according to the AAP guidelines. TcB measurements showed false negative results in the first 60 hours of life using both devices. After the 60th hour of life, TcB measurements using both devices successfully predicted newborn babies not at risk of significant hyperbilirubinemia, being the JM-103 more reliable than BC because of fewer false positive results.

Conclusions: Our study shows that both BC and JM-103 can exclude subsequent significant hyperbilirubinemia when the measurements are performed after the 60th hour of life. Nevertheless, the transcutaneous pre-discharge screening should be considered only as the first step, and it has to be followed by a follow-up through the first days after discharge.

Keywords: Newborn, Neonatal jaundice, Transcutaneous bilirubin measurements
Parents of infants with TSB <50th percentile were coun-
tered for hyperbilirubinemia using TSB measurement.

http://www.ijponline.net/content/39/1/46

only drug administered to studied infants. Breast or bottle
feeding every 3 hours was started within one hour of life.

Methods

Study population
This prospective cohort study was conducted through
January to July 2011 in a single maternity ward. Ethics com-
mite of the Department of Paediatrics approved the study
and the consent form. Informed consent was obtained from
both parents. The inclusion criteria were gestational age
≥ 35 weeks (based on ultrasound assessment in the first
trimester, if available or on postmenstrual age otherwise),
absence of congenital malformation and of any disease re-
quiring an admission to the neonatal intensive care unit.
Intramuscular administration of 1 mg vitamin K was the
only drug administered to studied infants. Breast or bottle
feeding every 3 hours was started within one hour of life.

Measurement of TcB and TSB

The measurement of TcB was performed on each baby
either when he/she was visually jaundiced and/or just
before discharge from the hospital. The determination of
TcB was made at the forehead with the two instruments
within 5 minutes, according to manufacturer instruc-
tions. BC was calibrated before each measurement using
a BiliCal™™, and each measurement was performed with 5
readings in different points of neonatal forehead. JM-
103 was used on the forehead performing 5 readings too.
Reading locations for both devices were distanced
from the hairline and free of any bruising, nevus, haem-
angioma or other skin anomalies. Each device was used
by one neonatologist unaware of the other one’s results
and of the TSB level. A blood sample (50 μl) for TSB
measurement was obtained by heel stick puncture, soon
after TcB measurement. Capillary tubes were protected
from ambient light and were assayed with direct spec-
trophotometer (Microbilimeter Dual Beam Plus model,
Ginevri, Rome, Italy) after centrifugation. A total of 627
paired-sample measurements were obtained from 298
newborn babies.

Follow-up of studied infants

Newborn babies were never discharged before 72 h of
age, independently from the mode of delivery. All new-
born babies with a pre-discharge TSB value > 75th per-
centile of our nomogram were discharged only after two
consecutive decreasing TSB values, 12 hours apart, mak-
ing us able to identify the peak TSB level. Newborn in-
fants with pre-discharge TSB level between the 50th and
the 75th percentile were discharged and controlled 48 h
later for hyperbilirubinemia using TSB measurement.

Outcome

Measurements of TcB were plotted on our percentile-
based hour-specific nomogram separately by two re-
searchers after completion of the study. Significant
hyperbilirubinemia was defined as TSB value >17 mg/dL,
or as need for phototherapy treatment according to the
AAP guidelines. Newborn babies with TcB value below
the 75th percentile that developed subsequent significant
hyperbilirubinemia were defined as false negative results.

Results

A total of 298 newborn babies (143 males and 155 fe-
males, 279 full term and 19 late preterm) were enrolled
in the study (Table 1). Mean gestational age (±SD) was
38.7 (1.4) weeks (range: 35–42) and mean birth weight
(BW) was 3200 (440) g (range: 1830–4430). The majority
of babies were Caucasian (92.3%) and were born after
spontaneous delivery (58.4%). Breast and/or bottle feed-
ing were the prevalent feeding methods, only 34.9% re-
ceived exclusive breastfeeding. Delayed meconium
passage (>24 h of life) was observed in 20 (6.7%) babies,
and only 12 (4.0%) had a weight loss greater than 10%.
Out of the total studied population, 16 newborn babies
(5.4%) were diagnosed as having significant hyper-
bilirubinemia, and 9 (3.0%) received phototherapy. None
of the babies required an exchange transfusion. No cases
of significant hyperbilirubinemia were noticed among not jaundiced babies. The mean variation coefficient for BC and JM-103 was 7.4% ± 1% and 6.9% ± 1.2%, respectively.

Table 2 shows the predictive ability of the 75th percentile of TcB nomogram to identify babies with significant hyperbilirubinemia using the TcB measurements obtained by BC and JM-103. TcB measurements using both the devices showed false negative results in the first 60 hours of life. In this period, BC values were more reliable than JM-103 values because of less false negatives, but with more false positives. After the 60th hour of life there were no false negative results for both the devices, but JM-103 was more reliable because of less false positive results.

The ROC curve for the 75th percentile of TcB is shown in Figure 1 where the true positive rate (sensitivity) was plotted in function of the false positive rate (1-specificity). The area under the ROC curve (AUC) measured the accuracy of the percentiles in predicting significant hyperbilirubinemia using JM-103 or BC. AUCs for both the devices were lower in the first 24–60 hours of life than between 61–96 hours. JM-103 had higher AUC than BC between 61–96 hours, and this difference borders statistical significance (p = 0.074).

In order to calculate the execution times of both procedures for a subset of 50 newborn babies, a second investigator clocked times for TcB measurements. Mean time for one TcB measurement was 41.2 (5.0) sec (range: 38–55 sec) for BC and 19.2 (2.6) sec (range: 16–25 sec) for JM-103. The longer time for BC was mainly due to the calibration procedure.

Discussion

Even if healthy term newborns are discharged in many countries before the 60th hour of life, this burdening problem is not yet clearly defined [26]. The Expert Committee for Severe Neonatal Hyperbilirubinemia and European Society for Pediatric Research and American Academy of Pediatrics published detailed recommendations emphasizing the importance of universal, systematic assessment of the risk of severe hyperbilirubinemia, suggesting that a systems-based approach to prevent severe neonatal hyperbilirubinemia should be implemented at all birthing facilities and coordinated with continuing ambulatory care [27]. Therefore, the identification of

### Table 1 Baseline characteristics of the study population

| Variables                        | Neonates (298) |
|----------------------------------|----------------|
| Gestational age (wks)            | 38.7 ± 1.4 |
| > 37                             | 279 (93.6) |
| 35 - 36                          | 19 (6.4)   |
| Birth weight (g)                 | 3200 ± 440 |
| Male                             | 143 (48.0) |
| Mode of delivery                 |              |
| Vaginal                          | 174 (58.4) |
| Cesarean section                 | 117 (39.3) |
| Ventouse                         | 7 (2.3)    |
| Feeding                          |              |
| Exclusive breast feeding         | 104 (34.9) |
| Breast + bottle feeding          | 160 (53.7) |
| Bottle feeding                   | 34 (11.4)  |
| Delayed meconium passage (>24 hrs) | 20 (6.7) |
| Weight loss >10%                 | 12 (4.0)   |
| Significant hyperbilirubinemia   | 16 (5.4)   |
| Required phototherapy            | 9 (3.0)    |
| TSB >17 mg/dL                    | 7 (2.3)    |

Values expressed as mean ± SD or number (%).

### Table 2 Ability of JM-103 and BC measurements below the 75th percentile of TcB nomogram (ref. [22]) to predict significant hyperbilirubinemia, for designated time periods

| Hours of age    | TP (n) | FN (n) | TN (n) | FP (n) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|-----------------|--------|--------|--------|--------|----------------|----------------|---------|---------|
| **JM 103**      |        |        |        |        |                |                |         |         |
| 24 to 48 hours  | 2      | 2      | 124    | 47     | 50.0           | 72.5           | 4.1     | 98.4    |
| 49 to 60 hours  | 4      | 1      | 79     | 21     | 80.0           | 79.0           | 16.0    | 98.8    |
| 61 to 72 hours  | 5      | 0      | 129    | 37     | 100            | 77.7           | 11.9    | 100     |
| 73 to 96 hours  | 13     | 0      | 117    | 46     | 100            | 71.8           | 22.0    | 100     |
| **Total**       | 24     | 3      | 449    | 151    | 88.9           | 74.8           | 13.7    | 99.3    |
| **Bilicheck**   |        |        |        |        |                |                |         |         |
| 24 to 48 hours  | 3      | 1      | 73     | 98     | 75.0           | 42.7           | 3.0     | 98.6    |
| 49 to 60 hours  | 4      | 1      | 45     | 55     | 80.0           | 45.0           | 6.8     | 97.8    |
| 61 to 72 hours  | 5      | 0      | 82     | 84     | 100            | 49.4           | 5.6     | 100     |
| 73 to 96 hours  | 13     | 0      | 73     | 90     | 100            | 44.8           | 12.6    | 100     |
| **Total**       | 25     | 2      | 273    | 327    | 92.6           | 45.5           | 7.1     | 99.3    |

TP True Positive, FN False Negative, TN True negative, FP False Positive, PPV Positive Predictive Value, NPV Negative Predictive Value.
newborn babies at risk of severe hyperbilirubinemia is still one of the most challenging problems for the neonatologist. The use of TSB measurement before discharge from the hospital reduced the number of babies with very high levels of bilirubin [5-8], but apparently it did not reduce the incidence of bilirubin-induced neurological damage [28]. TcB use to avoid TSB measurement, reducing the pain and risks of this procedure, progressively increased during the last years [9-15]. We recently validated our TcB nomogram in a large Italian prospective study, showing that 100% of sensitivity can be obtained with TcB measurements only after 48 hours of life, using the 75th percentile [22]. However, two recent papers from South Carolina and Canada raised some concerns because of false-negative results from pre-discharge TcB screening [29,30]. Moreover, it is not known if the hour specific TcB nomogram developed with measurements obtained with the BC could have the same predictivity when a different transcutaneous bilirubinometer is used. The present study was performed for this reason, in order to compare the predictive ability of BC vs JM-103 using our transcutaneous bilirubin nomogram built with the BC.

Our experience showed that 100% sensitivity was obtained after 60 hours of life for both devices, giving JM-103 less false positive results. In the first 60 hours of life there were false negative results with both devices.
(2 with BC and 3 with JM-103) but JM-103 had less false positive results. Furthermore, JM-103 was less time consuming and less expensive because of the absence of consuming materials.

Our data ask for caution when TcB measurements and TcB nomogram are used as predictive tools if an early (<60 hours) discharge from the hospital is performed. While our previous experience with BC showed the best predictive power after 48 hours of life, in this present work we had one false negative with both the devices between 48 and 60 hours of life. These false negative results would have not been identified even if the risk factors for hyperbilirubinemia suggested by Keren et al. and by Maisels et al. were applied [3,21]. In fact, both the infants were white, males, spontaneously delivered at 36 and 37 weeks of gestation, and had a normal clinical course in the first 72 hours of life. They were breast and bottle fed and had a normal weight loss (<7%). They were discharged at 72 hours of life and were controlled 48 hours later reaching their maximum bilirubin level (17.2 mg/dL) at 85 and 98 hours of life.

This study has some limitations: it is not a population-based study because the enrolment was based on clinical practice, it includes a vast majority of Caucasian newborn babies, and the incidence of significant hyperbilirubinemia is low. Their strengths are its robust design and the high follow-up rate for enrolled newborn babies. All babies referred to our ambulatory care facility for clinical evaluation after discharge, and no case of readmission for hyperbilirubinemia was noticed.

Conclusions
Our study shows that BC and JM-103 can be used for the TcB measurements to exclude significant hyperbilirubinemia after the 60th hour of life. Nevertheless, our experience suggests that the pre-discharge screening for hyperbilirubinemia should be considered only as the first step of a long route that ends only after an accurate follow-up through the first days after discharge. Therefore, we agree with Fay et al. [26] when they state that the follow-up for hyperbilirubinemia should not be discouraged by risk screening practice, without exposing newborn babies to unnecessary and unjustified risks.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
CR and EZ designed the study and have made substantial contributions in drafting manuscript. PC, LG, and RR performed data acquisition and validation. GB and PC contributed to interpretation of data and performed statistical analysis. AAZ verified data analysis and revised the manuscript critically. All authors read and approved the final manuscript.

Received: 1 February 2013 Accepted: 16 July 2013
Published: 23 July 2013

References
1. Maisels MJ, Kring E: Length of stay, jaundice, and hospital readmission. Pediatrics 1998, 101:995–998.
2. Ip S, Lau J, Chung M, Kulig J, Sege R, Glicken S, O’Brien R: Hyperbilirubinemia and kernicterus: 50 years later. Pediatrics 2004, 114:263–264.
3. Keren R, Luan X, Friedman S, Saddlemine S, Cnaan A, Bhutani VK: A comparison of alternative risk assessment strategies for predicting significant neonatal hyperbilirubinemia in term and near-term infants. Pediatrics 2008, 121:e170–e179.
4. Riskin A, Tamir A, Kugelman A, Hemo M, Bader D: Is Visual Assessment of jaundice reliable as a screening tool to detect significant neonatal hyperbilirubinemia? J Pediatr 2008, 152:762–767.
5. Bhutani VK, Johnson L, Sivieri JM: Predictive ability of a predischarge hour specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999, 103:6–14.
6. Burke BL, Robbins JM, Bird M, Hobbs CA, Nesmith C, Tilford JM: Trends in hospitalizations for neonatal jaundice and kernicterus in the United States, 1988–2005. Pediatrics 2009, 123:524–532.
7. Eggert LD, Weidmeyer SE, Wilson J, Christiansen RD: The effect of instituting a prehospital-discharge newborn bilirubin screening program in an 18-hospital health system. Pediatrics 2006, 117:e855–e862.
8. Mah MP, Clark SL, Akhigbe E, Englebright J, Fye DK, Meyers JA, Perlin JB, Rodriguez M, Shepard A: Reduction of significant hyperbilirubinemia after institution of predischarge bilirubinscreening. Pediatrics 2010, 125:e1143–e1148.
9. Maisels MJ, Kring E: Transcutaneous bilirubinometry decreases the need for serum bilirubin measurements and saves money. Pediatrics 1997, 99:599–601.
10. Keren R, Luan X, Friedman S, Saddlemine S, Cnaan A, Bhutani VK: Transcutaneous bilirubinometry reduces the need for blood sampling in neonates with visible jaundice. Acta Paediatr 2009, 98:1916–1919.
11. Cansell-Blanchard A, Cousineau I, Delvin EE: Point of care testing: Transcutaneous bilirubinometry in neonates. Clin Biochem 2009, 42:143–149.
12. Karon BS, Teske A, Santrach PJ, Cook WL: Evaluation of the BiliChek noninvasive bilirubin analyzer for prediction of serum bilirubin and risk of hyperbilirubinemia. Am J Clin Pathol 2008, 130:976–982.
13. Ahmed M, Mostafa S, Fisher G, Reynolds TM: Comparison between transcutaneous bilirubinometry and total serum bilirubin measurements in preterm infants <35 weeks gestation. Ann Clin Biochem 2010, 47:72–77.
14. Engle WD, Jackson GL, Sendelbach D, Manning D, Frawley WH: Assessment of a transcutaneous device in the evaluation of neonatal hyperbilirubinemia in a primarily Hispanic population. Pediatrics 2002, 110:61–67.
15. De Luca D, Zuppa AA, Cota F, Zecca E, Romagnoli C: Multiwavelength transcutaneous bilirubinometry: suitability and cost analysis. Ital J Pediatr 2008, 32:328–329.
16. Sanpavit S, Nuchprayoon I, Smathakanee C, Hansuebsai R: Nomogram for prediction of the risk of neonatal hyperbilirubinemia, using transcutaneous bilirubin. J Med Assoc Thai 2005, 88:1187–1193.
17. Maisels MJ, Kring E: Transcutaneous bilirubin levels in the first 96 hours in a normal newborn population of <35 weeks’ gestation. Pediatrics 2006, 117:1169–1173.
18. De Luca D, Romagnoli C, Tiberi E, Zuppa AA, Zecca E: Skin bilirubin nomogram for the first 96 h of life in a European normal healthy newborn population, obtained with multiwavelength transcutaneous bilirubinometry. Acta Paediatr 2008, 97:146–150.
19. Fouzas S, Mantagou I, Sklogianni E, Mantagos S, Vranitis A: Transcutaneous bilirubin levels for the first 120 postnatal hours in healthy neonates. Pediatrics 2010, 125:e52–e57.
20. Yu Z-B, Dong X-Y, Han S-P, Chen Y-L, Qiu Y-F, Sha L, Sun Q, Guo XR: Transcutaneous bilirubin nomogram for predicting neonatal hyperbilirubinemia in healthy term and late preterm Chinese infants. Eur J Pediatr 2011, 170:185–191.
21. Maisels MJ, Defidder JM, Kring EA, Balasubramaniam M: Routine transcutaneous bilirubin measurements combined with clinical risk factors improve the prediction of subsequent hyperbilirubinemia. J Perinatol 2009, 29:612–617.
22. Romagnoli C, Tiberi E, Barone G, De Curtis M, Regoli D, Paolillo P, Piconne S, Anania S, Finocchi M, Cardiello V, Zecca E: Validation of transcutaneous
bilirubin nomogram in identifying neonates not at risk of hyperbilirubinemia: A prospective, observational, multicenter study. Early Hum Dev 2012, 88:51–55.

23. Romagnoli C, Zecca E, Catenazzi P, Barone G, Zuppa AA: Transcutaneous bilirubin measurement: comparison of Respironics BiliCheck and JM-103 in a normal newborn population. Clin Biochem 2012, 45(9):659–662.

24. Raimondi F, Lama S, Landolfo F, Sellitto M, Borrelli AC, Maffucci R, Milite P, Capasso L: Measuring transcutaneous bilirubin: a comparative analysis of three devices on a multiracial population. BMC Pediatr 2012, 12:70.

25. AAP Subcommittee on Hyperbilirubinemia: Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004, 114:297–316.

26. Catz C, Hanson MV, Simpson L, Yaffe SI: Summary of workshop: early discharge and neonatal hyperbilirubinemia. Pediatrics 1995, 96:743–745.

27. Bhutani VK, Maisels MJ, Stark AR, Buonocore G: Expert Committee for Severe Neonatal Hyperbilirubinemia; European Society for Pediatric Research; American Academy of Pediatrics Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants > or = 35 weeks gestation. Neonatology 2008, 94(1):63–67.

28. Fay DL, Schellhase KG, Suresh GR: Bilirubin screening for normal newborns: a critique of the hour-specific bilirubin nomogram. Pediatrics 2009, 124:1203–1205.

29. Slaughter J, Annibale D, Suresh G: False-negative results of pre-discharge neonatal bilirubin screening to predict significant hyperbilirubinemia: a need for caution. Eur J Pediatr 2009, 168:1461–1466.

30. Rodriguez-Capote K, Kim K, Paes B, Turner D, Grey V: Clinical implication of the difference between transcutaneous bilirubinometry and total serum bilirubin for the classification of newborns at risk of hyperbilirubinemia. Clin Biochem 2009, 42:76–79.

doi:10.1186/1824-7288-39-46
Cite this article as: Romagnoli et al.: BiliCheck vs JM-103 in identifying neonates not at risk of hyperbilirubinemia. Italian Journal of Pediatrics 2013 39:46.